Second-generation antiandrogen has shown exciting clinical success, but many patients are intrinsically resistant to these agents. That resistance, plus the highly variable responses, largely limit the clinical benefit of antiandrogen treatment for prostate cancer. Therefore, there is an urgent need to identify novel biomarkers to predict the patients’ response to antiandrogen.
I have used an in vivo shRNA-based library screening to identify several novel tumor-suppressor genes, deletion of which confers significant resistance to antiandrogen. We will elucidate the molecular mechanisms of the resistance conferred by these tumor-suppressor genes, to examine the genes' utility as a novel biomarker for antiandrogen response.